KR100880760B1 - 항종양제로서 사용하기 위한 벤조일술폰아미드 및술포닐벤즈아미딘 - Google Patents

항종양제로서 사용하기 위한 벤조일술폰아미드 및술포닐벤즈아미딘 Download PDF

Info

Publication number
KR100880760B1
KR100880760B1 KR1020037015958A KR20037015958A KR100880760B1 KR 100880760 B1 KR100880760 B1 KR 100880760B1 KR 1020037015958 A KR1020037015958 A KR 1020037015958A KR 20037015958 A KR20037015958 A KR 20037015958A KR 100880760 B1 KR100880760 B1 KR 100880760B1
Authority
KR
South Korea
Prior art keywords
hydrogen
alkyl
halo
alkoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037015958A
Other languages
English (en)
Korean (ko)
Other versions
KR20040007656A (ko
Inventor
토마스 휴즈 코르벳
코라 수 그로스만
카렌 린 롭
추안 신
필립 아서 힙스킨드
호-쉔 린
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20040007656A publication Critical patent/KR20040007656A/ko
Application granted granted Critical
Publication of KR100880760B1 publication Critical patent/KR100880760B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
KR1020037015958A 2001-06-06 2002-05-24 항종양제로서 사용하기 위한 벤조일술폰아미드 및술포닐벤즈아미딘 Expired - Fee Related KR100880760B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06
US60/296,350 2001-06-06
PCT/US2002/015142 WO2002098848A1 (en) 2001-06-06 2002-05-24 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents

Publications (2)

Publication Number Publication Date
KR20040007656A KR20040007656A (ko) 2004-01-24
KR100880760B1 true KR100880760B1 (ko) 2009-02-02

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037015958A Expired - Fee Related KR100880760B1 (ko) 2001-06-06 2002-05-24 항종양제로서 사용하기 위한 벤조일술폰아미드 및술포닐벤즈아미딘

Country Status (35)

Country Link
US (1) US7183320B2 (cg-RX-API-DMAC7.html)
EP (1) EP1401806B1 (cg-RX-API-DMAC7.html)
JP (1) JP4167173B2 (cg-RX-API-DMAC7.html)
KR (1) KR100880760B1 (cg-RX-API-DMAC7.html)
CN (1) CN100475787C (cg-RX-API-DMAC7.html)
AR (1) AR036079A1 (cg-RX-API-DMAC7.html)
AT (1) ATE335722T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002259204B2 (cg-RX-API-DMAC7.html)
BR (1) BR0210078A (cg-RX-API-DMAC7.html)
CA (1) CA2446719A1 (cg-RX-API-DMAC7.html)
CR (1) CR7182A (cg-RX-API-DMAC7.html)
CY (1) CY1105386T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033296A3 (cg-RX-API-DMAC7.html)
DE (1) DE60213810T2 (cg-RX-API-DMAC7.html)
DK (1) DK1401806T3 (cg-RX-API-DMAC7.html)
EA (1) EA005810B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034874A (cg-RX-API-DMAC7.html)
EG (1) EG24356A (cg-RX-API-DMAC7.html)
ES (1) ES2269688T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20031000A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0400114A3 (cg-RX-API-DMAC7.html)
IL (1) IL158985A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03011197A (cg-RX-API-DMAC7.html)
MY (1) MY136855A (cg-RX-API-DMAC7.html)
NO (1) NO20035366L (cg-RX-API-DMAC7.html)
NZ (1) NZ529098A (cg-RX-API-DMAC7.html)
PE (1) PE20030199A1 (cg-RX-API-DMAC7.html)
PL (1) PL367188A1 (cg-RX-API-DMAC7.html)
PT (1) PT1401806E (cg-RX-API-DMAC7.html)
SK (1) SK14642003A3 (cg-RX-API-DMAC7.html)
SV (1) SV2003001076A (cg-RX-API-DMAC7.html)
TW (1) TWI266761B (cg-RX-API-DMAC7.html)
UA (1) UA74889C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002098848A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308644B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316984T2 (de) 2002-11-22 2008-07-17 Eli Lilly And Co., Indianapolis Benzoylsulfonamide als antitumor-mittel
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
ATE542796T1 (de) * 2004-05-26 2012-02-15 Abbott Lab N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
KR20070114774A (ko) * 2005-02-28 2007-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 혈관 신생 저해 물질과의 신규 병용
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
EP2015070A4 (en) 2006-04-20 2010-04-21 Eisai R&D Man Co Ltd Novel marker for sensitivity against sulfonamide compound
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
WO2008138594A1 (en) * 2007-05-16 2008-11-20 F. Hoffmann-La Roche Ag Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ616828A (en) * 2009-01-19 2015-03-27 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
AU2011229862B2 (en) * 2010-03-25 2014-07-24 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
EA036995B1 (ru) 2015-02-13 2021-01-25 Оксфорд Драг Дизайн Лимитед НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
WO2018237163A1 (en) * 2017-06-23 2018-12-27 Roman Manetsch 5-aminolevulinate synthase inhibitors and methods of use thereof
TWI822719B (zh) * 2017-12-29 2023-11-21 共信醫藥科技股份有限公司 苯磺醯胺衍生物及調節脂膜筏之方法
CN114790149B (zh) * 2021-01-26 2024-11-19 江苏中旗科技股份有限公司 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法
WO2025031361A1 (zh) * 2023-08-09 2025-02-13 上海科技大学 磺酰胺类化合物作为制备治疗癌症药物的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
JPH05169834A (ja) * 1991-12-25 1993-07-09 Oji Paper Co Ltd 感熱記録体
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
CA2110524A1 (en) 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
ATE239698T1 (de) 1995-10-25 2003-05-15 Senju Pharma Co Angiogenese hemmer
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO2000047215A2 (en) * 1999-02-12 2000-08-17 Cellpath, Inc. Methods for anti-tumor therapy
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
JPH05169834A (ja) * 1991-12-25 1993-07-09 Oji Paper Co Ltd 感熱記録体
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Also Published As

Publication number Publication date
CN1514824A (zh) 2004-07-21
UA74889C2 (en) 2006-02-15
AU2002259204B2 (en) 2008-01-17
KR20040007656A (ko) 2004-01-24
JP2004530709A (ja) 2004-10-07
CR7182A (es) 2004-06-08
HRP20031000A2 (en) 2004-04-30
SV2003001076A (es) 2003-07-29
NZ529098A (en) 2005-08-26
EA005810B1 (ru) 2005-06-30
BR0210078A (pt) 2004-06-22
ATE335722T1 (de) 2006-09-15
JP4167173B2 (ja) 2008-10-15
EP1401806A1 (en) 2004-03-31
WO2002098848A1 (en) 2002-12-12
NO20035366D0 (no) 2003-12-02
IL158985A0 (en) 2004-05-12
CA2446719A1 (en) 2002-12-12
US7183320B2 (en) 2007-02-27
AR036079A1 (es) 2004-08-11
CY1105386T1 (el) 2010-04-28
HUP0400114A2 (hu) 2005-04-28
HK1064360A1 (en) 2005-01-28
DE60213810T2 (de) 2007-02-01
ECSP034874A (es) 2004-01-28
EG24356A (en) 2009-03-04
NO20035366L (no) 2004-02-06
SK14642003A3 (sk) 2004-12-01
CZ20033296A3 (cs) 2004-04-14
PL367188A1 (en) 2005-02-21
ES2269688T3 (es) 2007-04-01
ZA200308644B (en) 2005-02-07
DE60213810D1 (de) 2006-09-21
CN100475787C (zh) 2009-04-08
DK1401806T3 (da) 2006-11-27
PT1401806E (pt) 2006-11-30
HUP0400114A3 (en) 2007-05-02
TWI266761B (en) 2006-11-21
PE20030199A1 (es) 2003-03-12
EA200400006A1 (ru) 2004-06-24
US20040157741A1 (en) 2004-08-12
MXPA03011197A (es) 2004-02-26
EP1401806B1 (en) 2006-08-09
MY136855A (en) 2008-11-28

Similar Documents

Publication Publication Date Title
EP1401806B1 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
AU2002259204A1 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
JP2004530709A5 (cg-RX-API-DMAC7.html)
KR100913471B1 (ko) 항신생물제로서의 티오펜- 및 티아졸술폰아미드
US20090118323A1 (en) Antitumor benzoylsulfonamides
EP4140998B1 (en) Substituted pyridazinone compound and use thereof
JP2025531874A (ja) 代謝疾患及びがんの治療のためのミトコンドリア脱共役剤
CN111943906B (zh) 脒类衍生物、及其制法和药物组合物与用途
HK1064360B (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
CN111253325A (zh) 氨基喹唑啉芳基哌嗪类化合物及其药物组合物和应用
CN111138422A (zh) 一种用于防治红斑狼疮的药物及其制备方法
JPH02202857A (ja) アミノアルコキシベンゼン誘導体
KR20010013163A (ko) 세포 증식 억제제로서의 시아노아미딘
HK1068337B (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120121

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120121